Figure 1From: Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancerProgression-free survival (PFS) in patents with platinum refractory or resistant epithelial ovarian cancer.Back to article page